Active Infection & Immunity Cancer

Clonal and functional T cell determinants of protection and pathogenesis in tuberculosis.

In plain English

AI plain-English summary

Every year, tuberculosis kills 1.5 million people, yet most people infected with the bacterium *Mycobacterium tuberculosis* never develop active disease. T cells are essential for this protection, but scientists do not know exactly which traits of these immune cells separate a successful defence from a full-blown illness. People living with HIV remain at persistently high risk of TB even after long-term antiretroviral therapy, and their T cell repertoires show lasting abnormalities. This project will compare the Mtb-reactive T cells of treated HIV-positive individuals with those of HIV-negative people, testing whether the dominant T cells in the HIV group are less diverse, target different bacterial antigens, or function differently. The team will then determine which of these T cell traits actually control how well macrophages stop Mtb from growing, and test whether those traits predict TB risk in large population cohorts. If successful, this research could directly inform vaccine design—by identifying which T cell responses a vaccine should elicit—and enable personalised risk-stratification, allowing clinicians to target preventative antibiotics to those most likely to develop active TB. It may also point toward immunomodulatory therapies that restore protective T cell function in vulnerable groups.

View original technical description
Tuberculosis (TB), resulting from infection with Mycobacterium tuberculosis (Mtb), kills 1.5 million people per year. The immune system prevents disease in most people who become infected, but the mechanisms of immune protection and pathogenesis remain critical knowledge gaps. T cells are necessary for protective immunity, but we do not know the precise T cell traits that influence different outcomes of infection. People living with HIV (PLWH) have persistently increased TB disease-risk and exhibit persistent abnormalities of T cell clonal and functional repertoires, despite long-term antiretroviral therapy (ART). We will use cutting-edge methodology to comprehensively detail perturbation of in vivo human Mtb-reactive T cell responses in this group, independent of total T cell counts. We will test the hypothesis that dominant Mtb-reactive T cells in ART-treated PLWH have restricted clonality, target different antigens and exhibit different functionality, compared to those of HIV-negative individuals. We will identify which of these T cell traits impact on macrophage control of Mtb-growth, and predict disease-risk in multiple independent cohorts sampled from the general population. We expect our findings to drive innovations in vaccine development and evaluation, personalised risk-stratification to enable precision targeting of preventative antimicrobial treatment, and development of immunomodulatory therapies for disease.

View the original record at the funder ↗

Researchers

Andreas Tiffeau-Mayer (EPMC Awardee)Benjamin Chain (EPMC Awardee)Hans Stauss (EPMC Awardee)Mahdad Noursadeghi (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Investigating T cell compromise of macrophage defence in tuberculosis
Defining protective immunity to human tuberculosis.
Investigating local determinants of outcome in human tuberculosis
Trained immunity in the pathogenesis of tuberculosis
Investigating the functional role of CD1 expression and defining protective and pathogenic CD1c-immunity in tuberculosis.

Original classification

Discovery Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.